Global Necrotizing Fasciitis Treatment Market Introduction
Necrotizing fasciitis (NF) is rare bacterial infection of soft tissues also known as flesh eating disease. Causative agent of necrotizing fasciitis is bacterium (monomicrobial NF) or several bacteria (polymicrobial NF). The bacteria infect the subcutaneous tissue and the tissue that covers internal organs. Necrotizing fasciitis is a rapidly progressive inflammatory infection of the fascia, with secondary necrosis of the subcutaneous tissues. Polymicrobial NF mostly occurs in individuals who are immunocompromised, while monomicrobial NF is less common and affects healthy individuals who often have a history of trauma.
According to the Centers for Disease Control and Prevention (CDC), 500 to 1,000 cases of necrotizing fasciitis are diagnosed in the U.S. each year. Necrotizing fasciitis treatment involves surgery to remove infected tissues, and antibiotics & supportive treatment to control blood pressure, organ function, and fluid levels.
Global Necrotizing Fasciitis Treatment Market - Competitive Landscape
The global necrotizing fasciitis treatment market is consolidated with several domestic players holding key market share in respective regions. High cost of research and development and time taken for clinical trial process are also attributed to market consolidation. The global necrotizing fasciitis treatment market is attracting large number of domestic manufacturers. Major players operating in the global necrotizing fasciitis treatment market focus on business expansion and engage in mergers and collaborations.
Stuck in a Neck-to-Neck Competition with Other Brands? Request a Custom Report on “Necrotizing Fasciitis Treatment Market” here
Merck & Co., Inc.
Merck & Co., Inc. is a global health care company that develops, manufactures, markets, and sells vaccines and pharmaceuticals. Its products are utilized by health care professionals in more than 100 countries. It periodically invests in acquisitions that provide opportunities to supplement organic growth as well as strengthen its product portfolio and expand business in emerging markets.
Merck & Co., Inc. has wide presence in various regions including Asia Pacific, Europe, Middle East & Africa, and Latin America. It offers innovative health solutions in more than 140 countries.
Pfizer, Inc. is a multinational company with strong presence in necrotizing fasciitis treatment market in North America. Pfizer, Inc. is a global pharmaceutical company that develops, manufactures, and markets prescription medicines in 11 therapeutic segments, including cardiovascular, oncology, neuroscience, pain, and infectious diseases. It operates through two business units: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
GlaxoSmithKline plc is a global pharmaceutical company that engages in research, development, and manufacture of innovative pharmaceutical medicines, vaccines, and consumer health care products. In 2018, GlaxoSmithKline invested around US$ 4.60 Mn in research and development of pipeline products.
Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a key producer of generic medicines and a recognized leader in innovative and specialty pharmaceuticals across the globe. The company delivers high-quality and patient-centric health care solutions across the globe. It has a broad generic product portfolio with more than 35,000 products in nearly every therapeutic area. The company operates through two business segments: generic medicines and specialty medicines. Teva Pharmaceutical Industries Ltd. markets its gout therapeutic drug under its generic medicines business segment.
Other players operating in the global necrotizing fasciitis treatment market include Bristol-Myers Squibb Company and Abbott.
Need an Overview of the Report on Necrotizing Fasciitis Treatment Market? Ask for the Brochure here
Necrotizing Fasciitis Treatment Market - Dynamics
Anticipated launch and commercialization of drugs to drive market
A large number of drug candidates are in different stages of clinical trials in the U.S. and Europe. The anticipated launch and commercialization of these products is expected to propel the global necrotizing fasciitis treatment market during the forecast period. Rise in health care expenditure drives demand for research and development of biologics and biosimilars for treatment of necrotizing fasciitis.
Increase in incidence of necrotizing fasciitis to drive market
An article published by NCBI stated that incidence of NF ranges from 500 to 1000 per year, while the global prevalence is 0.40 cases per 100,000 population. The global necrotizing fasciitis treatment market is projected to grow at a rapid pace during the forecast period.
Favorable health care policies lead to increase in affordability of various health care treatments. This, in turn, increases the life expectancy of the population. However, stringent government regulations for sale of over-the-counter necrotizing fasciitis drugs, lack of awareness about the disease in developing economies, and poor reimbursement policies in developed countries are likely to restrain the global necrotizing fasciitis treatment market.
Necrotizing Fasciitis Treatment Market - Segmentation
In terms of drug type, the global necrotizing fasciitis treatment market can be classified into:
- Penicillin G
Based on type, the global necrotizing fasciitis treatment market can be categorized into:
- Type I
- Type II
- Type III
- Type IV
In terms of distribution channel, the global necrotizing fasciitis treatment market can be divided into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.